Combination Therapy with the Histone Deacetylase Inhibitor LBH589 and Radiation Is an Effective Regimen for Prostate Cancer Cells

The emerging role of histone deacetylase (HDAC) inhibitors in urological cancers

(2013) Naomi L. Sharma et al.   BJU INTERNATIONAL

Histone deacetylase inhibitors as radiosensitisers: effects on DNA damage signalling and repair

(2013) B Groselj et al.   BRITISH JOURNAL OF CANCER

Epigenetics and persistent memory: implications for reconsolidation and silent extinction beyond the zero

(2013) K Matthew Lattal et al.   NATURE NEUROSCIENCE

Enhancement of radiosensitivity by a unique novel NF-κB inhibitor, DHMEQ, in prostate cancer

(2012) N Kozakai et al.   BRITISH JOURNAL OF CANCER

Developing Histone Deacetylase Inhibitors as Anti-Cancer Therapeutics

(2011) B. Venugopal et al.   CURRENT MEDICINAL CHEMISTRY

Retention of the In Vitro Radiosensitizing Potential of Gemcitabine Under Anoxic Conditions, in p53 Wild-Type and p53-Deficient Non–Small-Cell Lung Carcinoma Cells

(2011) An Wouters et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Low-Dose Valproic Acid Enhances Radiosensitivity of Prostate Cancer through Acetylated p53-Dependent Modulation of Mitochondrial Membrane Potential and Apoptosis

(2011) X. Chen et al.   MOLECULAR CANCER RESEARCH

Co-expression of CD147 (EMMPRIN), CD44v3-10, MDR1 and monocarboxylate transporters is associated with prostate cancer drug resistance and progression

(2010) J Hao et al.   BRITISH JOURNAL OF CANCER

A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer

(2010) Dana Rathkopf et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Monoclonal antibody targeting MUC1 and increasing sensitivity to docetaxel as a novel strategy in treating human epithelial ovarian cancer

(2010) Li Wang et al.   CANCER LETTERS

Coexpression of invasive markers (uPA, CD44) and multiple drug-resistance proteins (MDR1, MRP2) is correlated with epithelial ovarian cancer progression

(2009) H Chen et al.   BRITISH JOURNAL OF CANCER

Enhancing the apoptotic and therapeutic effects of HDAC inhibitors

(2009) Ailsa J. Frew et al.   CANCER LETTERS

Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors

(2009) H Miles Prince et al.   Future Oncology

Postradiation Sensitization of the Histone Deacetylase Inhibitor Valproic Acid

(2008) P. Chinnaiyan et al.   CLINICAL CANCER RESEARCH

DNA-damage repair; the good, the bad, and the ugly

(2008) Razqallah Hakem   EMBO JOURNAL